Modern's Effectiveness In Preventing Hospitalization

Moderna's COVID-19 vaccine has been found to be highly effective in preventing hospitalizations. According to various studies, Moderna's vaccine has been shown to be more effective than other vaccines, such as Pfizer and Johnson & Johnson's vaccines, in reducing the risk of hospitalization due to COVID-19. The Moderna vaccine offers strong protection against hospitalization, especially for high-risk patients with underlying medical conditions. While all authorized vaccines provide substantial protection, Moderna's vaccine has consistently demonstrated higher effectiveness in preventing hospitalizations, making it a preferred choice for individuals and healthcare systems.

Moderna's vaccine is 93% effective at preventing COVID-19 hospitalisations

Moderna's COVID-19 vaccine has been found to be highly effective in preventing hospitalisations. According to a study by the CDC, Moderna's vaccine is 93% effective at preventing COVID-19 hospitalisations, compared to 88% for Pfizer's and 71% for Johnson & Johnson's. The study included thousands of US adults admitted to hospitals from March to August and showed that Moderna's vaccine offered better protection against hospitalisation.

Another study by researchers from Harvard T.H. Chan School of Public Health and other institutions found that the Moderna vaccine was slightly more effective than the Pfizer vaccine in preventing COVID-19 hospitalisations. The study showed that Pfizer recipients had a 70% higher risk of COVID-19 hospitalisation when the Alpha variant was predominant, and a slightly higher risk during the Delta variant's dominance as well.

Moderna's vaccine has also been found to be more effective in preventing hospitalisations in high-risk patients with underlying medical conditions compared to the Pfizer-BioNTech vaccine. A real-world analysis showed that Moderna's mRNA-1273.222 bivalent vaccine was significantly more effective in preventing COVID-19-related hospitalisations in adults with one or more underlying medical conditions. This highlights the importance of focusing on immunocompromised and high-risk individuals in the context of COVID-19 vaccination.

While all three vaccines authorised by US regulators provide substantial protection against COVID-19 hospitalisations, Moderna's vaccine stands out with its 93% effectiveness. This information can guide individual choices and policy recommendations regarding vaccine boosters, ensuring maximum protection against the disease.

Moderna's vaccine is more effective than Pfizer's at preventing hospitalisations

Moderna's COVID-19 vaccine has been found to be more effective than Pfizer's in preventing hospitalisations. According to a study by the CDC, Moderna's vaccine is 93% effective in preventing hospitalisations, compared to 88% for Pfizer's. Another study found that Moderna's vaccine was 95% effective, while Pfizer's was 80% effective. This difference in effectiveness may be due to Moderna's higher vaccine dose and longer interval between shots.

The Moderna vaccine has consistently shown a slightly lower risk of COVID-19 outcomes, including hospitalisation, over various time periods and across different variants. For example, during a 12-week period when the Delta variant was predominant, the risk of hospitalisation was found to be higher in the Pfizer group. Similarly, for adults with underlying medical conditions, Moderna's vaccine was found to be significantly more effective in preventing COVID-19-related hospitalisations.

In terms of overall effectiveness, both vaccines remain highly effective at preventing severe illness and hospitalisations. However, the Moderna vaccine has shown a slight advantage in protecting against hospitalisations, especially for high-risk patients and older individuals. This highlights the importance of vaccine availability and discussions with healthcare professionals to determine the best option for each patient.

While the choice between the two vaccines is important for larger decision-making bodies, it is worth noting that comparative safety was not the focus of the studies. Both the Moderna and Pfizer vaccines offer strong protection, and either one is strongly recommended for individuals. The availability of these vaccines has played a crucial role in the fight against COVID-19 and its severe outcomes.

Moderna's vaccine is more effective for high-risk patients

Moderna's COVID-19 vaccine has been found to be more effective in preventing hospitalisation in high-risk patients compared to other vaccines. Moderna's vaccine is 93% effective at preventing COVID-19 hospitalisations, compared to 88% for Pfizer's and 71% for Johnson & Johnson's.

A real-world analysis showed that Moderna's mRNA-1273.222 vaccine was significantly more effective than Pfizer-BioNTech's BNT162b2 vaccine in preventing COVID-19-related hospitalisations in adults with one or more underlying medical conditions. This analysis included 1,962,547 adults, with 38.6% having received the Moderna vaccine and 61.4% the Pfizer vaccine.

Another study by the CDC found that Pfizer's vaccine was 91% effective against hospitalisations within 120 days of the second dose, but its effectiveness dropped to 77% after that. In contrast, Moderna's effectiveness only dropped by one point, from 93% to 92%, over the same period.

The higher effectiveness of Moderna's vaccine may be due to the higher dose and longer interval between shots compared to Pfizer's vaccine. The Moderna vaccine has also been found to be more effective in preventing infections during the Delta surge.

While Moderna's vaccine has shown slightly better effectiveness, it is important to note that both vaccines remain effective at preventing severe illness and providing strong protection against hospitalisation. Healthcare systems and organisations should consider these differences when making decisions for large populations.

Moderna's vaccine is more effective for adults with underlying medical conditions

Moderna's COVID-19 vaccine has been found to be more effective than other vaccines in preventing hospitalizations, especially for adults with underlying medical conditions. Moderna's vaccine is 93% effective at preventing COVID-19 hospitalizations, compared to 88% for Pfizer's and 71% for Johnson & Johnson's. The study included thousands of US adults admitted to hospitals from March to August.

A separate study by researchers from the CAUSALab at Harvard T.H. Chan School of Public Health also found that the Moderna vaccine was slightly more effective than Pfizer's in preventing COVID-19 hospitalizations. This pattern was consistent during periods when the Alpha or Delta variants were predominant.

Another study compared the effectiveness of Moderna's mRNA-1273.222 vaccine with the BNT162b2 vaccine developed by Pfizer-BioNTech in adults with one or more underlying medical conditions. The results showed that Moderna's vaccine was significantly more effective in preventing COVID-19-related hospitalizations and outpatient encounters in this high-risk group.

These findings highlight the importance of vaccination for individuals with underlying medical conditions, who are at a higher risk of severe disease. While all authorized vaccines provide substantial protection, Moderna's vaccine offers a slightly higher level of protection for adults with underlying health issues.

Moderna's vaccine is more effective for older individuals

Moderna's COVID-19 vaccine has been found to be more effective at preventing hospitalisation than other vaccines, including Pfizer and Johnson & Johnson. Moderna's vaccine is 93% effective at preventing COVID-19 hospitalisations, compared to 88% for Pfizer and 71% for Johnson & Johnson.

Moderna's vaccine has also been found to be more effective for older individuals, with a 96% effectiveness rate in preventing hospitalisation for those aged 65-74, and 96% for those aged 75 and older. In comparison, Pfizer's vaccine was 96% effective for those aged 65-74 and 91% effective for those 75 and older, while Johnson & Johnson's vaccine was 84% effective for both age groups.

The higher effectiveness of Moderna's vaccine may be due to the higher dose and longer interval between shots compared to Pfizer's vaccine. Moderna's vaccine has also been found to be more effective at preventing infections during the Delta surge and has a slightly lower risk of COVID-19 outcomes, including documented SARS-CoV-2 infection, symptomatic COVID-19, and COVID-19-related hospitalisation.

While Moderna's vaccine has shown greater effectiveness overall, it is important to note that both the Moderna and Pfizer vaccines are highly effective in preventing severe illness and hospitalisation, especially for older individuals.

Frequently asked questions